Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 10/20 | 1.00 |
| ▸ | PARP1 | P09874 | 1/20 | 1.00 |
| ▸ | PIM1 | P11309 | 3/20 | 0.65 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.65 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.57 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1299778 | 1.00 | HPGD (1.00) | HPGDPARP1PIM1PIM2AKR1B1 | |
| SCHEMBL6865386 | 1.00 | HPGD (1.00) | HPGDPARP1PIM1PIM2AKR1B1 | |
| SCHEMBL12406319 | 0.88 | PARP1 (0.79) | HPGDPARP1PIM1PIM2AKR1B1 | |
| SCHEMBL2174761 | 0.88 | PARP1 (0.79) | HPGDPARP1PIM1PIM2AKR1B1 | |
| SCHEMBL2174757 | 0.88 | PARP1 (0.79) | HPGDPARP1PIM1PIM2AKR1B1 | |
| SCHEMBL12521789 | 0.85 | HPGD (0.74) | HPGDPARP1PIM1PIM2AKR1B1 | |
| SCHEMBL2173324 | 0.83 | HPGD (0.71) | HPGDPARP1PIM1PIM2PTGS2 | |
| SCHEMBL2173328 | 0.83 | HPGD (0.71) | HPGDPARP1PIM1PIM2PTGS2 | |
| SCHEMBL12406324 | 0.83 | HPGD (0.71) | HPGDPARP1PIM1PIM2PTGS2 | |
| SCHEMBL12406318 | 0.83 | HPGD (0.70) | HPGDPARP1CISD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174951-B2 | Glucose transporter inhibitors | OHIO STATE INNOVATION FOUNDATION (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150051255-A1 | GLUCOSE TRANSPORTER INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2015-02-19 | — | — | US | disclosed |
| EP-2383263-B1 | NOVEL THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF | UNIV CHOSUN IACF (KR) | 2014-04-16 | — | — | EP | disclosed |
| US-8637558-B2 | Thiazolidinedione derivative and use thereof | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, CHOSUN UNIVERSITY (KR) | 2014-01-28 | — | — | US | disclosed |
| WO-2013148994-A1 | GLUCOSE TRANSPORTER INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-10-03 | — | — | WO | disclosed |
| US-8309582-B2 | Small molecule Bcl-Xl/Bcl-2 binding inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-11-13 | — | — | US | disclosed |
| US-20110269954-A1 | NOVEL THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, CHOSUN UNIVERSITY (KR) | 2011-11-03 | — | — | US | disclosed |
| EP-2383263-A2 | NOVEL THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF | Industry-academic Cooperation Foundation, Chosun University (KR) | 2011-11-02 | — | — | EP | disclosed |
| US-7973062-B2 | Androgen receptor-ablative agents | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100168184-A1 | SMALL MOLECULE BCL-X1/BCL-2 BINDING INHIBITORS | NATIONAL INSTITUTES OF HEALTH | 2010-07-01 | — | — | US | disclosed |
| US-7714005-B2 | Small molecule Bcl-xL/Bcl-2 binding inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-05-11 | — | — | US | disclosed |
| US-20090291992-A1 | ANDROGEN RECEPTOR-ABLATIVE AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-11-26 | — | — | US | disclosed |
| US-7566787-B2 | Small molecule cyclin D1 ablative agents | THE OHIO STATE UNIVERSITY (US) | 2009-07-28 | — | — | US | disclosed |
| US-20060252802-A1 | Small molecule cyclin D1 ablative agents | NIH - DEITR | 2006-11-09 | — | — | US | disclosed |
| US-20060252801-A1 | Small molecule Bcl-xL/Bcl-2 binding inhibitors | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252801-A1 | Small molecule Bcl-xL/Bcl-2 binding inhibitors | BCL2L1, BCL2, BCL2L2 | HPGD 2010/4885PARP1 83/4885PIM1 1940/4885 |
| US-20090291992-A1 | ANDROGEN RECEPTOR-ABLATIVE AGENTS | AR, ESRRB, KLK3 | HPGD 183/4885PARP1 1402/4885PIM1 4023/4885 |
| US-20110269954-A1 | NOVEL THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF | HPGD, CYP27B1, GCDH | HPGD 1/4885PARP1 3763/4885PIM1 4115/4885 |
| US-20150051255-A1 | GLUCOSE TRANSPORTER INHIBITORS | SLC2A4, SLC2A1, SLC2A2 | HPGD 1548/4885PARP1 4635/4885PIM1 2534/4885 |
| US-20060252802-A1 | Small molecule cyclin D1 ablative agents | CDK4, CCNK, CCNA1 | HPGD 597/4885PARP1 390/4885PIM1 591/4885 |
| US-20100168184-A1 | SMALL MOLECULE BCL-X1/BCL-2 BINDING INHIBITORS | BCL2, BCL2L1, BCL2A1 | HPGD 1917/4885PARP1 80/4885PIM1 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.